Recent Quotes (30 days)

You have no recent quotes
chg | %

Sophiris Bio Inc  

(Public, TSE:SHS)   Watch this stock  
Find more results for TSE:PRX
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 4.25 - 18.20
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -4.35
Shares     -
Beta     -
Inst. own     -
May 15, 2017
Q1 2017 Sophiris Bio Inc Earnings Release (Estimated) Add to calendar
Apr 5, 2017
Sophiris Bio Inc at Needham Healthcare Conference
Mar 27, 2017
Q4 2016 Sophiris Bio Inc Earnings Release
Mar 13, 2017
Sophiris Bio Inc at ROTH Conference
Feb 2, 2017
Sophiris Bio Inc at PR Newswire and BetterInvesting (NAIC) Life Sciences & Healthcare Investor Conference

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -7.10% -57.41%
Return on average equity -15.18% -137.57%
Employees 9 -
CDP Score - -


1258 Prospect St
LA JOLLA, CA 92037-3609
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links


Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.

Officers and directors

Lars G. Ekman M.D., Ph.D. Chairman of the Board
Age: 66
Randall E. Woods President, Chief Executive Officer, Director
Age: 64
Peter T. Slover CPA Chief Financial Officer
Age: 40
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development, Director
Age: 52
John Geltosky Ph.D. Independent Director
Age: 69
James Leslie Heppell Independent Director
Age: 60
Gerald T. Proehl Independent Director
Age: 56